C3(1)/TAg-REAR mice allow transplantation of TAg-expressing tumors and/or cell lines in the FVB/N genetic background, and are a novel immunocompetent transplant model for studying basal-like triple negative breast cancer, prostate tumors from TRAMP mice, C3(1)/TAg tumor cell lines, etc. In contrast to the higher-transgene copy C3(1)/TAg line (Stock No. 013591) from which it was derived, C3(1)/TAg-REAR mice have only one copy (or a partial copy) of the transgene - resulting in retained tolerance to SV40 TAg but no spontaneous cancer phenotype.
Jeffrey E Green, National Cancer Institute, National Institutes of Health (NIH/NCI)
Olga Aprelikova, National Cancer Institute, National Institutes of Health (NIH/NCI)
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Inserted expressed sequence) |
The C3(1)/TAg transgene has the 5' flanking region of the rat prostatic steroid binding protein gene [C3(1)] directing expression of the early region of simian virus 40 large tumor antigen (TAg) to prostate and mammary gland tissues. The original C3(1)/TAg founder line C contained ~six transgene copies at a single locus in the telomeric portion of chromosome 6 (which contains the Ki-ras proto-oncogene) - resulting in multistage oncogenesis in prostate and mammary gland (see Stock No. 013591).
From that original line, the C3(1)/TAg-REAR subline (Stock No. 030386) was identified with transgene rearrangement/deletion to only one copy (or a partial copy) in the original chromosome 6 locus. As a result, C3(1)/TAg-REAR mice exhibit no spontaneous cancer phenotype and retain immunological tolerance to cells expressing TAg (including tumors from the C3(1)/TAg and TRAMP models). C3(1)/TAg-REAR have a normally functioning immune system - as evidenced by a normal complement of subclasses of immune cells and the rejection of both human tumor cells and murine tumors derived from a non-FVB/N background. Additionally, induction of an anti-tumor immune response can be elicited in C3(1)/TAg-REAR mice (e.g., irradiated C3(1)/TAg tumor cell vaccination significantly inhibits growth of injected C3(1)/TAg-derived mammary fat pad tumors). Furthermore, C3(1)/TAg tumors or cell lines can be implanted synchronously into the mammary fat pads of large cohorts of immunocompetent C3(1)/TAg-REAR mice - this bypasses the need to wait for tumors to develop spontaneously in multiple transgenic mice over a variable time course and allows therapeutic interventions to be performed in a relatively short timeframe.
Mice hemizygous or homozygous for the C3(1)/TAg-REAR transgene are viable and fertile with normal breeding, and no spontaneous overt phenotype.
The C3(1)/TAg transgene was designed by Dr. Jeffrey E. Green (NIH/NCI) to have the 5prime flanking region of the rat prostatic steroid binding protein gene [C3(1)] followed by the sequences encoding the early region of simian virus 40 large tumor antigen (TAg).
The C3(1)/TAg transgene was microinjected into FVB/N fertilized oocytes. Founder line C was established with ~six copies of the transgene integrated at a single locus in the telomeric portion of chromosome 6 (which contains the Ki-ras proto-oncogene). C3(1)/TAg founder line C was maintained on the FVB/N genetic background (see Stock No. 013591). Routine screening of Dr. Green’s C3(1)/TAg founder line C colony identified female transgenic mice that retained tolerance to SV40 TAg but did not develop the expected phenotype (mammary tumors). These females were bred to FVB/NCrl wildtype males to propagate the new subline, called C3(1)/TAg-REAR. Characterization of C3(1)/TAg-REAR revealed a transgene rearrangement had occurred that deleted most of the original transgene copies - apparently leaving only one copy (or a partial copy) of the transgene in the original chromosome 6 locus. The C3(1)/TAg-REAR subline was then maintained by breeding hemizygous C3(1)/Tag-REAR males with FVB/NCrl females.
In 2017, Dr. Green sent albino males hemizygous for the C3(1)/TAg-REAR transgene on the FVB/N genetic background to The Jackson Laboratory as Stock No. 030386. Upon arrival, sperm was cryopreserved. To establish our living colony, an aliquot of the frozen sperm was used to fertilize FVB/NJ oocytes (Stock No. 001800).
Expressed Gene | TAg, SV40 large T-antigen, SV40 |
---|---|
Site of Expression |
Allele Name | transgene insertion c, Jeffrey E Green |
---|---|
Allele Type | Transgenic (Inserted expressed sequence) |
Allele Synonym(s) | C3(1)/SV40; C3(1)/SV40T; C3(1)/T antigen (Tag); C3(1)/T(AG); C3(1)/TAg; C3(1)-SV40 T antigen; C3(1)-Tag; C3Tag; C3-TAg; Large T; Tg(Scgb2a2-TAg)cJeg |
Gene Symbol and Name | Tg(C3-1-TAg)cJeg, transgene insertion c, Jeffrey E Green |
Gene Synonym(s) | |
Promoter | C3(1), C3(1), rat |
Expressed Gene | TAg, SV40 large T-antigen, SV40 |
Strain of Origin | FVB/N |
Chromosome | UN |
Molecular Note | This transgene contains the rat prostatic binding protein C3 promoter (Pbpc3) and the wild-type allele of the SV40 large tumor antigen (TAg) gene. Founder c carried 6 copies of the transgene. Founders f, g, i, j, k, and l were also generated. Two transgenic lines (c and l) were produced. |
Mutations Made By | Jeffrey Green, National Cancer Institute, National Institutes of Health (NIH/NCI) |
Mice hemizygous or homozygous for the C3(1)/TAg-REAR transgene are viable and fertile with normal breeding, and no spontaneous overt phenotype.
When maintaining a live colony, hemizygous mice may be bred together, to wildtype mice from the colony or to FVB/NJ inbred mice (Stock No. 001800). Alternatively, homoxygous mice may be bred together.
When using the C3(1)/Tag-REAR mouse strain in a publication, please cite the originating article(s) and include JAX stock #030386 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or non-carrier for Tg(C3-1-TAg)cJeg |
Frozen Mouse Embryo | FVB/N-Tg(C3-1-TAg)cJeg/2JegJ | $2595.00 |
Frozen Mouse Embryo | FVB/N-Tg(C3-1-TAg)cJeg/2JegJ | $2595.00 |
Frozen Mouse Embryo | FVB/N-Tg(C3-1-TAg)cJeg/2JegJ | $3373.50 |
Frozen Mouse Embryo | FVB/N-Tg(C3-1-TAg)cJeg/2JegJ | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.